Response to: 'Severe COVID-19 associated pneumonia in 3 patients with systemic sclerosis treated with rituximab' by Avouac et al
- PMID: 32503848
- DOI: 10.1136/annrheumdis-2020-217955
Response to: 'Severe COVID-19 associated pneumonia in 3 patients with systemic sclerosis treated with rituximab' by Avouac et al
Keywords: B-Lymphocytes; autoantibodies; rituximab.
Conflict of interest statement
Competing interests: PG has been a medical expert for LFB (Laboratoire Français du Biofractionnement) and has received fees from AbbVie, Actelion, Boehringer Ingelheim France, Bouchara-Recordati, Novartis, Pfizer and Roche in the last 5 years. ATJM has received fees from AbbVie, Actelion, CSL Behring, Experf, Novartis and Shire and declares speaking fees from AstraZeneca and BMS in the last 5 years.
Comment on
-
Rituximab for granulomatosis with polyangiitis in the pandemic of covid-19: lessons from a case with severe pneumonia.Ann Rheum Dis. 2021 Jan;80(1):e10. doi: 10.1136/annrheumdis-2020-217549. Epub 2020 Apr 20. Ann Rheum Dis. 2021. PMID: 32312768 No abstract available.
-
Severe COVID-19-associated pneumonia in 3 patients with systemic sclerosis treated with rituximab.Ann Rheum Dis. 2021 Mar;80(3):e37. doi: 10.1136/annrheumdis-2020-217864. Epub 2020 Jun 5. Ann Rheum Dis. 2021. PMID: 32503849 No abstract available.